What does XTL Biopharmaceuticals Ltd. do?

XTL Biopharmaceuticals Ltd. (XTLB.TA) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is XTLB.TA's market cap?

XTL Biopharmaceuticals Ltd. (XTLB.TA) has a market capitalization of approximately $1.80 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does XTLB.TA pay a dividend?

No — XTL Biopharmaceuticals Ltd. (XTLB.TA) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is XTLB.TA profitable?

XTL Biopharmaceuticals Ltd. (XTLB.TA) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

XTLB.TA

XTL Biopharmaceuticals Ltd.

TLV·Biotechnology · Healthcare

ILA 1.90ILA 0.10−5.00%

Market capILA 1.80B·Aug 26 2:24 PM UTC

Price Chart

ILA 1.90−ILA 0.10 (−5.00%)today

+1,166.67%CAGR +66.17%

Select date range

FromTo

Aug 30, 2005Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

XTLB.TA does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateDec 3

Last Report DateDec 31

Reported vs Estimate−ILA 0.00

Earnings Surprise—

FinancialsFinancials Tab

Revenue$451.00K

Net Income−$1.03M

Net Margin−227.7%

Operating Cash Flow$0.00

Capital Expenditures$0.00

Free Cash Flow$0.00

Return on Equity—

Return on Invested Capital0.0%

Net Debt$125.00K

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for XTLB.TA and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how XTLB.TA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for XTLB.TA and 80,000+ other tickers.

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to sourcing and advancing medicinal products aimed at treating autoimmune conditions. Its principal experimental compound, hCDR1, is primed for Phase II clinical studies, addressing systemic lupus erythematosus and Sjogren's syndrome. The company operates under a licensing agreement with Yeda Research and Development Company Limited, granting it rights for the research, development, and commercialization of hCDR1 across numerous therapeutic applications. Originally incorporated in 1993 as Xenograft Technologies Ltd., the entity…

CEO: Noam Band
Sector: Healthcare
Industry: Biotechnology
Exchange: TLV
Employees: 10
Website: www.xtlbio.com

Peers

Tikun Olam-Cannbit Pharmaceuticals Ltd.

Cap

ILA 212.9K

Latest News

News Tab

XTL Announces Receipt of Staff Delist Determination from Nasdaq
RAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE: XTLB. TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated May 18, 2026, notifying the Company that since the Company has not yet filed its Annual Report on Form 20-F for the year ended December 31, 2025, it no longer complies with Nasdaq's Listing Rule Listing Rule 5250(c)(1) which requires companies to timely file all required periodic financial reports with the SEC.
globenewswire.comMay 22, 2026 · 4:10 PM

Frequently Asked Questions About XTLB.TA

What does XTL Biopharmaceuticals Ltd. do?: XTL Biopharmaceuticals Ltd. (XTLB.TA) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is XTLB.TA's market cap?: XTL Biopharmaceuticals Ltd. (XTLB.TA) has a market capitalization of approximately $1.80 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does XTLB.TA pay a dividend?: No — XTL Biopharmaceuticals Ltd. (XTLB.TA) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is XTLB.TA profitable?: XTL Biopharmaceuticals Ltd. (XTLB.TA) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

XTL Biopharmaceuticals Ltd.

Frequently Asked Questions About XTLB.TA

XTL Biopharmaceuticals Ltd.

XTL Announces Receipt of Staff Delist Determination from Nasdaq

Frequently Asked Questions About XTLB.TA

XTL Announces Receipt of Staff Delist Determination from Nasdaq